SUBJECTS : Biliary Tract Diseases | Liver Disease
Clinical and Molecular Hepatology: 2023, vol: , issue:
- 1)- Vy H Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H Nguyen. Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study. Clinical and molecular hepatology. 2023, 29 (4): 1002-1012
Cited : 1Read More - 2)- Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim. Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis. Clinical and molecular hepatology. 2023, 29 (4): 1013-1028Cited : 3Read More
- 3)- Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon. Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection. Clinical and molecular hepatology. 2023, 29 (4): 1029-1042Cited : 0Read More
- 4)- Daphne J Theodorou, Stavroula J Theodorou, Ioannis V Mitselos. Letter regarding "Evidence-based hyponatremia management in liver disease". Clinical and molecular hepatology. 2023, 29 (4): 1043-1045Cited : 1Read More
- 5)- Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh. Letter regarding "Risk factors in nonalcoholic fatty liver disease". Clinical and molecular hepatology. 2023, 29 (4): 1046-1047Cited : 1Read More
- 6)- Ji Young Ryu, Seon Ha Baek, Sejoong Kim. Correspondence on Letter regarding "Evidence-based hyponatremia management in liver disease". Clinical and molecular hepatology. 2023, 29 (4): 1048-1049Cited : 0Read More
- 7)- Eileen L Yoon, Dae Won Jun. Correspondence on Letter regarding "Risk factors in nonalcoholic fatty liver disease". Clinical and molecular hepatology. 2023, 29 (4): 1050-1051Cited : 0Read More
- 8)- Qiankun Luo, Pan Liu, Yifei Dong, Tao Qin. The role of the hepatic autonomic nervous system. Clinical and molecular hepatology. 2023, 29 (4): 1052-1055Cited : 0Read More
- 9)- Gi-Ae Kim, Joon Ho Moon, Won Kim. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity. Clinical and molecular hepatology. 2023, 29 (4): 831-843Cited : 20Read More
- 10)- Eileen L Yoon, Dae Won Jun. Waiting for the changes after the adoption of steatotic liver disease. Clinical and molecular hepatology. 2023, 29 (4): 844-850Cited : 15Read More
- 11)- Landon L Chan, Stephen L Chan. The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment. Clinical and molecular hepatology. 2023, 29 (4): 909-923Cited : 5Read More
- 12)- Ji Young Ryu, Seon Ha Baek, Sejoong Kim. Evidence-based hyponatremia management in liver disease. Clinical and molecular hepatology. 2023, 29 (4): 924-944Cited : 4Read More
- 13)- Hwa Kyung Byun, Changhwan Kim, Jinsil Seong. Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma. Clinical and molecular hepatology. 2023, 29 (4): 945-957Cited : 3Read More
- 14)- Sung Uk Lee, Tae Hyun Kim. Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma. Clinical and molecular hepatology. 2023, 29 (4): 958-968Cited : 2Read More
- 15)- Ming-Lun Yeh, Ming-Lung Yu. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials. Clinical and molecular hepatology. 2023, 29 (4): 969-972Cited : 4Read More
- 16)- Jacob George. Adding to the confusion in more than just the name. Clinical and molecular hepatology. 2023, 29 (4): 973-976Cited : 5Read More
- 17)- Sang Min Yoon. Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy. Clinical and molecular hepatology. 2023, 29 (4): 977-979Cited : 0Read More
- 18)- Eugene Han, Yong-Ho Lee. Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean? Clinical and molecular hepatology. 2023, 29 (4): 980-983Cited : 1Read More
- 19)- Hyo-Cheol Kim. Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma? Clinical and molecular hepatology. 2023, 29 (4): 984-986Cited : 0Read More
- 20)- Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe. Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity. Clinical and molecular hepatology. 2023, 29 (4): 987-1001Cited : 9Read More
- 21)- Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim, . Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clinical and molecular hepatology. 2023, 29 (3): 521-541Cited : 7Read More
- 22)- Xianhua Mao, Lung Yi Mak, Wai-Kay Seto. The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B. Clinical and molecular hepatology. 2023, 29 (3): 690-692Cited : 1Read More
- 23)- Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clinical and molecular hepatology. 2023, 29 (3): 763-778Cited : 3Read More
- 24)- Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee. Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma. Clinical and molecular hepatology. 2023, 29 (3): 794-809Cited : 1Read More
- 25)- Hassam Ali. Letter 1 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clinical and molecular hepatology. 2023, 29 (3): 813-814Cited : 0Read More
- 26)- Amnuay Kleebayoon, Viroj Wiwanitkit. Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clinical and molecular hepatology. 2023, 29 (3): 815-816Cited : 1Read More
- 27)- Seul Ki Han, Soon Koo Baik, Moon Young Kim. Correspondence on Letter regarding "Non-alcoholic fatty liver disease: Definition and subtypes". Clinical and molecular hepatology. 2023, 29 (3): 817-819Cited : 0Read More
- 28)- Joo Hyun Oh, Dong Hyun Sinn. Correspondence on Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?". Clinical and molecular hepatology. 2023, 29 (3): 820Cited : 0Read More
- 29)- Yee Hui Yeo, Jamil S Samaan, Wee Han Ng. Correspondence on Letter 1 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clinical and molecular hepatology. 2023, 29 (3): 821-822Cited : 2Read More
- 30)- Yee Hui Yeo, Jamil S Samaan, Wee Han Ng. Correspondence on Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clinical and molecular hepatology. 2023, 29 (3): 823-824Cited : 2Read More
- 31)- Soon Kyu Lee, Jung Hyun Kwon. HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations? Clinical and molecular hepatology. 2023, 29 (3): 825-827Cited : 0Read More
- 32)- Joo Hyun Oh, Dong Hyun Sinn. Erratum to 'Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?' [Clin Mol Hepatol 2023;29:367-370]. Clinical and molecular hepatology. 2023, 29 (3): 828-829Cited : 0Read More
- 33)- Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong. Erratum to 'Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in directacting antiviral failure in South Korea' [Clin Mol Hepatol 2023;29:496-509]. Clinical and molecular hepatology. 2023, 29 (3): 830Cited : 0Read More
- 34)- Yee Hui Yeo, Ju Dong Yang. Disseminating Steatotic Liver Disease Patient Education: The Emerging Role of Large Language Models. Clinical and molecular hepatology. 2023, : Cited : 1Read More
- 35)- Miguel Sogbe, Idoia Bilbao, Francesco P Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D'Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro. Prognostic Value of Ultra-Low-Pass Whole-Genome Sequencing of Circulating Tumor DNA in hepatocellular carcinoma under systemic treatment. Clinical and molecular hepatology. 2023, : Cited : 1Read More
- 36)- Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen. Evaluating the Therapeutic Efficacy of NAD Supplementation in Management of MASLD: Key Considerations. Clinical and molecular hepatology. 2023, : Cited : 0Read More
- 37)- Ying-Nan Tsai, Jia-Ling Wu, Cheng-Hao Tseng, Tzu-Haw Chen, Yi-Ling Wu, Chieh-Chang Chen, Yu-Jen Fang, Tzeng-Huey Yang, Mindie H Nguyen, Jaw-Town Lin, Yao-Chun Hsu. Hepatitis B Core-Related Antigen Dynamics and Risk of Subsequent Clinical Relapses after Nucleos(t)ide Analog Cessation. Clinical and molecular hepatology. 2023, : Cited : 6Read More
- 38)- Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zhongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu. Protein-Centric Omics Analysis Reveals Circulating Complements Linked to Non-Viral Liver Diseases as Potential Therapeutic Targets. Clinical and molecular hepatology. 2023, : Cited : 2Read More
- 39)- Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi. Changing from NAFLD to MASLD: Similar Cumulative Incidence of Reflux Esophagitis between NAFLD and MASLD. Clinical and molecular hepatology. 2023, : Cited : 6Read More
- 40)- Eileen L Yoon, Dae Won Jun. Correspondence on a Letter regarding "Waiting for the changes after the adoption of steatotic liver disease (MASLD)". Clinical and molecular hepatology. 2023, : Cited : 0Read More
- 41)- Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi. Cardiovascular Risk in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. Clinical and molecular hepatology. 2023, : Cited : 4Read More
- 42)- Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Chia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu. TASL-TSOC Taiwan Position Statement for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Diseases. Clinical and molecular hepatology. 2023, : Cited : 2Read More
- 43)- Kuo Chao Yew, Sunny H Wong, Vincent Wai-Sun Wong, Hazel H Oon. It is time to consider a new paradigm shift in Steatotic Liver Disease in Asia. Clinical and molecular hepatology. 2023, : Cited : 1Read More
- 44)- Soomin Ahn, Sook-Hyang Jeong, Eun Ju Cho, Kyoungbun Lee, Gilhyang Kim, Haeryoung Kim. Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity. Clinical and molecular hepatology. 2023, : Cited : 2Read More
- 45)- Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, , Tien Yin Wong, Hongwei Ji. Assessing State-of-the-Art Online Large Language Models for Patient Education Regarding Steatotic Liver Disease. Clinical and molecular hepatology. 2023, : Cited : 1Read More
- 46)- Kamya Sankar, Jun Gong, Arsen Osipov, Steven A Miles, Kambiz Kosari, Nicholas N Nissen, Andrew E Hendifar, Ekaterina K Koltsova, Ju Dong Yang. Recent advances in the management of hepatocellular carcinoma. Clinical and molecular hepatology. 2023, : Cited : 7Read More
- 47)- Seon Ha Baek, Ji Young Ryu, Sejoong Kim. Erratum to 'Correspondence on Letter regarding "Evidencebased hyponatremia management in liver disease"' [Clin Mol Hepatol 2023;29:1048-1049]. Clinical and molecular hepatology. 2023, : Cited : 0Read More
- 48)- Hinpetch Daungsupawong, Viroj Wiwanitkit. Comment on "ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma.". Clinical and molecular hepatology. 2023, : Cited : 0Read More
- 49)- Young Chang, Soung Won Jeong, Jae Young Jang. Recent Updates on Pharmacologic Therapy in Nonalcoholic Fatty Liver Disease. Clinical and molecular hepatology. 2023, : Cited : 2Read More
- 50)- Chi Hsiao, Yung-Po Liaw. Letter regarding "Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma". Clinical and molecular hepatology. 2023, : Cited : 0Read More
